Pluri Inc. Launches Regenerative Aesthetic Products in U.S. Market
- Significant Market Potential: Pluri Inc.'s regenerative aesthetic products are expected to enter the U.S. market in 2026, coinciding with projections that the U.S. medical aesthetics market will reach $90 billion by 2030, indicating robust growth potential.
- Product Launch Progress: Cellav Health and Aesthetics Ltd. has completed the development and U.S. cosmetic product listings for Regenativo+ and Placento+, marking a significant step in the company's commercialization efforts in the U.S. market.
- Clinical Validation Support: The ingredients in Cellav's products have shown statistically significant improvements in skin elasticity and firmness, reinforcing its premium positioning in the professional regenerative and longevity sectors.
- Strategic Partnership Opportunities: Cellav is actively engaging with U.S. distributors and clinic networks to establish strategic partnerships and expand market share, aiming to drive future commercial growth.
Trade with 70% Backtested Accuracy
Analyst Views on PLUR
About PLUR
About the author
Pluri Inc. Launches Regenerative Aesthetic Products in U.S. Market
- Significant Market Potential: Pluri Inc.'s regenerative aesthetic products are expected to enter the U.S. market in 2026, coinciding with projections that the U.S. medical aesthetics market will reach $90 billion by 2030, indicating robust growth potential.
- Product Launch Progress: Cellav Health and Aesthetics Ltd. has completed the development and U.S. cosmetic product listings for Regenativo+ and Placento+, marking a significant step in the company's commercialization efforts in the U.S. market.
- Clinical Validation Support: The ingredients in Cellav's products have shown statistically significant improvements in skin elasticity and firmness, reinforcing its premium positioning in the professional regenerative and longevity sectors.
- Strategic Partnership Opportunities: Cellav is actively engaging with U.S. distributors and clinic networks to establish strategic partnerships and expand market share, aiming to drive future commercial growth.
Pluri Secures $2.5 Million Investment from Chairman
- Chairman's Investment: Pluri Inc. announced that its Chairman Alejandro Weinstein has entered into a Securities Purchase Agreement for an additional $2.5 million investment, executed at a 30% premium to the market price on March 24, 2026, reflecting his strong confidence in the company's long-term value creation potential.
- Investment Context: This additional investment follows Weinstein's prior $2.5 million investment, underscoring his recognition of Pluri's unique asset and technology combination, aimed at unlocking the company's potential value through focused execution and strategic prioritization.
- Financing Details: The private placement consists of 625,000 common shares and warrants to purchase an equal number of shares, with a purchase price of $4.00 per share and an exercise price of $4.25 for the warrants, expected to generate approximately $2.5 million in gross proceeds for the company.
- Use of Funds: Pluri intends to utilize the proceeds from this financing for general working capital and corporate purposes, further advancing its innovations in regenerative medicine, foodtech, and agtech sectors.
Pluri Expands Manufacturing Agreement with Remedy Cell to Support Clinical Trials
- Manufacturing Capability Enhancement: Pluri's collaboration with Remedy Cell successfully integrates its proprietary manufacturing process into Pluri's GMP facility, marking the completion of clinical-grade batch production that supports Remedy Cell's initial Phase 1b clinical trial, showcasing the strong synergy in biopharmaceutical development between the two companies.
- Clinical Trial Preparation: The successful manufacture of several clinical-grade batches signifies significant progress for Remedy Cell in its clinical development for treating complex fibrotic diseases, further advancing the clinical application of its secretome-based therapies to meet the urgent market demand for innovative treatment options.
- Expanded Collaboration Scope: PluriCDMO™ will continue to provide additional manufacturing and process development support for Remedy Cell, underscoring their shared commitment to advancing next-generation cell-free biologics that address significant unmet medical needs.
- Successful Technology Implementation: The successful execution of GMP training and engineering runs by Pluri's CDMO division not only enhances the robustness and scalability of the manufacturing process but also solidifies Pluri's position as a trusted partner for complex cell-derived therapies.
Pluri Collaborates with Miss Universe Skincare to Launch Exosome-Enhanced Regenerative Skincare Line
Launch of Cellav: Pluri Inc. has launched Cellav Health and Aesthetics Ltd., a subsidiary focused on developing advanced exosome-based technologies for medical aesthetics using Pluri's proprietary 3D cell expansion platform.
Collaboration with Miss Universe Skincare: Cellav has secured a partnership with Miss Universe Skincare to co-develop a new line of cell-based skincare products, with the first product expected to launch in the first half of 2026.
Market Potential: The beauty market is projected to reach $194.05 billion by 2032, highlighting the significant growth opportunity for Cellav's innovative skincare solutions.
Leadership and Vision: Cellav is led by CEO Katty Dowery, who emphasizes the integration of advanced biotechnology into everyday beauty products, aiming to make regenerative science accessible and impactful.
Plurilock Security Inc. Announces Financial Results for the Second Quarter of Fiscal Year 2025
Financial Performance: Plurilock Security Inc. reported a 159% increase in Critical Services revenue year-over-year and a 42% improvement in Adjusted EBITDA loss for Q2 2025 compared to the same period in 2024.
Revenue Breakdown: Total revenue for Q2 2025 was CAD 16.4 million, with significant contributions from professional services and software sales, while hardware sales decreased as a percentage of total revenue.
Operational Highlights: The company secured new contracts worth CAD 5.9 million across federal and public sector clients and expanded its presence in NATO and other international defense markets.
Future Outlook: Plurilock aims to continue its growth strategy focused on higher-margin offerings and is well-positioned to benefit from increased government spending in cybersecurity and defense sectors.
BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials
Partnership Announcement: BrainStorm Cell Therapeutics has signed a Letter of Intent with Minaris Advanced Therapies to manufacture its investigational therapy NurOwn® for an upcoming Phase 3b clinical trial, enhancing its manufacturing capabilities in the U.S.
Therapeutic Overview: NurOwn® utilizes autologous mesenchymal stem cells to produce neurotrophic factor-secreting cells aimed at treating neurodegenerative diseases like ALS, and has received Orphan Drug designation from both the FDA and EMA.
Pluri Inc. Launches Regenerative Aesthetic Products in U.S. Market
- Significant Market Potential: Pluri Inc.'s regenerative aesthetic products are expected to enter the U.S. market in 2026, coinciding with projections that the U.S. medical aesthetics market will reach $90 billion by 2030, indicating robust growth potential.
- Product Launch Progress: Cellav Health and Aesthetics Ltd. has completed the development and U.S. cosmetic product listings for Regenativo+ and Placento+, marking a significant step in the company's commercialization efforts in the U.S. market.
- Clinical Validation Support: The ingredients in Cellav's products have shown statistically significant improvements in skin elasticity and firmness, reinforcing its premium positioning in the professional regenerative and longevity sectors.
- Strategic Partnership Opportunities: Cellav is actively engaging with U.S. distributors and clinic networks to establish strategic partnerships and expand market share, aiming to drive future commercial growth.
Pluri Secures $2.5 Million Investment from Chairman
- Chairman's Investment: Pluri Inc. announced that its Chairman Alejandro Weinstein has entered into a Securities Purchase Agreement for an additional $2.5 million investment, executed at a 30% premium to the market price on March 24, 2026, reflecting his strong confidence in the company's long-term value creation potential.
- Investment Context: This additional investment follows Weinstein's prior $2.5 million investment, underscoring his recognition of Pluri's unique asset and technology combination, aimed at unlocking the company's potential value through focused execution and strategic prioritization.
- Financing Details: The private placement consists of 625,000 common shares and warrants to purchase an equal number of shares, with a purchase price of $4.00 per share and an exercise price of $4.25 for the warrants, expected to generate approximately $2.5 million in gross proceeds for the company.
- Use of Funds: Pluri intends to utilize the proceeds from this financing for general working capital and corporate purposes, further advancing its innovations in regenerative medicine, foodtech, and agtech sectors.
Pluri Expands Manufacturing Agreement with Remedy Cell to Support Clinical Trials
- Manufacturing Capability Enhancement: Pluri's collaboration with Remedy Cell successfully integrates its proprietary manufacturing process into Pluri's GMP facility, marking the completion of clinical-grade batch production that supports Remedy Cell's initial Phase 1b clinical trial, showcasing the strong synergy in biopharmaceutical development between the two companies.
- Clinical Trial Preparation: The successful manufacture of several clinical-grade batches signifies significant progress for Remedy Cell in its clinical development for treating complex fibrotic diseases, further advancing the clinical application of its secretome-based therapies to meet the urgent market demand for innovative treatment options.
- Expanded Collaboration Scope: PluriCDMO™ will continue to provide additional manufacturing and process development support for Remedy Cell, underscoring their shared commitment to advancing next-generation cell-free biologics that address significant unmet medical needs.
- Successful Technology Implementation: The successful execution of GMP training and engineering runs by Pluri's CDMO division not only enhances the robustness and scalability of the manufacturing process but also solidifies Pluri's position as a trusted partner for complex cell-derived therapies.
Pluri Collaborates with Miss Universe Skincare to Launch Exosome-Enhanced Regenerative Skincare Line
Launch of Cellav: Pluri Inc. has launched Cellav Health and Aesthetics Ltd., a subsidiary focused on developing advanced exosome-based technologies for medical aesthetics using Pluri's proprietary 3D cell expansion platform.
Collaboration with Miss Universe Skincare: Cellav has secured a partnership with Miss Universe Skincare to co-develop a new line of cell-based skincare products, with the first product expected to launch in the first half of 2026.
Market Potential: The beauty market is projected to reach $194.05 billion by 2032, highlighting the significant growth opportunity for Cellav's innovative skincare solutions.
Leadership and Vision: Cellav is led by CEO Katty Dowery, who emphasizes the integration of advanced biotechnology into everyday beauty products, aiming to make regenerative science accessible and impactful.
Plurilock Security Inc. Announces Financial Results for the Second Quarter of Fiscal Year 2025
Financial Performance: Plurilock Security Inc. reported a 159% increase in Critical Services revenue year-over-year and a 42% improvement in Adjusted EBITDA loss for Q2 2025 compared to the same period in 2024.
Revenue Breakdown: Total revenue for Q2 2025 was CAD 16.4 million, with significant contributions from professional services and software sales, while hardware sales decreased as a percentage of total revenue.
Operational Highlights: The company secured new contracts worth CAD 5.9 million across federal and public sector clients and expanded its presence in NATO and other international defense markets.
Future Outlook: Plurilock aims to continue its growth strategy focused on higher-margin offerings and is well-positioned to benefit from increased government spending in cybersecurity and defense sectors.
BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials
Partnership Announcement: BrainStorm Cell Therapeutics has signed a Letter of Intent with Minaris Advanced Therapies to manufacture its investigational therapy NurOwn® for an upcoming Phase 3b clinical trial, enhancing its manufacturing capabilities in the U.S.
Therapeutic Overview: NurOwn® utilizes autologous mesenchymal stem cells to produce neurotrophic factor-secreting cells aimed at treating neurodegenerative diseases like ALS, and has received Orphan Drug designation from both the FDA and EMA.
